Drug Profile
Research programme: hyaluronic acid-based rheumatoid arthritis therapeutic - Anika Therapeutics/University of Massachusetts Amherst
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Anika Therapeutics; University of Massachusetts Amherst
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 27 Feb 2018 Anika Therapeutics has issued and pending patents for Hyaluronic acid-based technology in countries worldwide
- 24 Jan 2018 Anika Therapeutics expands strategic research collaboration with the Institute for Applied Life Sciences to develop rheumatoid arthritis therapeutics